BIOSYNTHESIS OF ANTIBIOTICS OF THE VIRGINIAMYCIN FAMILY, 5.¹ THE CONVERSION OF PHENYLALANINE TO PHENYLGLYCINE IN THE BIOSYNTHESIS OF VIRGINIAMYCIN S₁

JOSEPHINE W. REED and DAVID G.I. KINGSTON*

Department of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061

ABSTRACT.—Conversion of L-phenylalanine to L-phenylglycine in the biosynthesis of virginiamycin S₁ (1) can, in principle, take place with intramolecular nitrogen transfer or with intermolecular nitrogen transfer. A labeling experiment with DL-[3-¹³C, ¹⁵N]phenylalanine showed that the resulting L-phenylglycine contained no labeled nitrogen, indicating that the rearrangement proceeds via an intermolecular pathway.

Virginiamycin $S_1(1)$ is a macrocyclic peptidolactone antibiotic produced by *Streptomyces virginiae* and a few other closely related *Streptomyces* species (2-4). Its structure rests both on chemical degradations (4) and on an X-ray crystal structure (5), and its ¹H-nmr and ¹³C-nmr spectra have been assigned as part of a study of its conformation in solution (6). It contains the protein amino acids L-threonine and L-proline, but its major constituents are the less common amino acids D-2-aminobutanoic acid, *N*-methyl-L-phenylalanine, 4-oxo-L-pipecolic acid, L-phenylglycine, and 3-hydrox-ypicolinic acid. In this paper we report the result of an experiment designed to elucidate the biosynthetic origin of the phenylglycine unit of virginiamycin S₁ from phenylalanine (**2**).



Although the phenylglycine unit (3) is relatively rare in natural products, its *N*-methyl derivative, L- α -phenylsarcosine (4), occurs in the related antibiotic etamycin, produced by *Streptomyces griseoviridus* (7,8). Biosynthetic results on this antibiotic support a pathway for the phenylalanine (2) to phenylsarcosine (4) conversion, which involves loss of the carboxyl group, migration of the amino group from the original α -carbon to the β -carbon, oxidation of the α -carbon to a carboxyl group, and *N*-methylation (9).

Although the broad outline of the pathway from phenylalanine to phenylsarcosine (4) or phenylglycine (3) is clear from the above work, there remain questions about the

¹For Part 4, see LeFevre and Kingston (1).

details of the pathway. One question of interest to us was whether the migration of the amino nitrogen atom is intermolecular or intramolecular. Reasonable mechanistic pathways can be advanced for both pathways. Thus, the intermolecular pathway (Scheme 1) could involve transamination to phenylpyruvic acid, decarboxylation and oxidation to benzoylformic acid, and transamination to phenylglycine, with the amino group coming from an external donor such as glutamine (Pathway A). Alternatively, a phenylalanine ammonia-lyase catalyzed deamination to cinnamic acid followed by reamination would give β -phenylalanine in an analogous fashion to a proposal for the conversion of tyrosine to β -tyrosine (10); final conversion to phenylglycine would be by decarboxylation and oxidation (Pathway B). An intramolecular pathway could involve an aziridinium intermediate 5, so that nitrogen always remains covalently bonded to the carbon skeleton. Opening of the ring by attack at the α -carbon would give a Schiff base, which would be converted to β -phenylalanine and thence to phenylglycine (pathway C). A similar pathway has been proposed for the biosynthesis of the β -lysine unit of streptothricin (11). Alternatively, pathways A or B could presumably occur in such a way that the originally eliminated nitrogen is returned without exchange. It should also be noted that although specific pathways are proposed for illustrative purposes, other plausible pathways exist.





In view of these reasonable possibilities for either type of reaction, we carried out experiments to test whether transformation of phenylalanine to phenylglycine proceeds by an intramolecular or intermolecular pathway.

RESULTS AND DISCUSSION

As a part of our investigation of the biosynthesis of virginiamycin S_1 , we had already tested L-[U-¹⁴C]phenylalanine as a precursor and shown it to be specifically incorporated into the N-methyl-L-phenylalanine and L-phenylglycine units of the antibiotic (12). In order to test the intermolecular or intramolecular nature of the phenylalanine to phenylglycine conversion, we elected to use the doubly labeled compound DL-[β -¹³C, ¹⁵N]phenylalanine hydrochloride. If rearrangement proceeds intermolecularly, the resulting phenylglycine would contain a ¹³C-label at the α -position but not any ¹⁵Nlabel. On the other hand, an intramolecular pathway would yield a phenylglycine in which both the amino nitrogen and the α -carbon were labeled, and such labeling of adjacent atoms would be detectable by observation of a ¹³C-¹⁵N coupling of a few Hertz in its ¹³C-nmr spectrum.

The synthesis of the doubly labeled precursor was achieved by standard methods, which were adapted to the case at hand (13-16). The ¹³C-nmr spectrum of the labeled phenylalanine showed the expected resonances and couplings. Thus, C_{β} appeared as an intense singlet at 35.56 ppm, while C_{α} appeared as a doublet of doublets with J=32.9 and 6.5 Hz for the one-bond ¹³C-¹³C and ¹³C-¹⁵N couplings, respectively. The Ar-1 carbon also appeared as a doublet with J=43.4 Hz.

Growth of S. virginiae in a medium enriched with DL-[β -¹³C, ¹⁵N]phenylalanine yielded, as expected, an antibiotic in which both the N-methylphenylalanine and the phenylglycine units were enriched in ¹³C. The ¹³C-nmr spectrum of the labeled antibiotic showed intense resonances at 36.7 ppm and 56.1 ppm, corresponding to the β carbon of N-methylphenylalanine and the α -carbon of phenylglycine, respectively (6). The resonance at 56.1 pm was examined carefully under high resolution conditions and was found to show no sign of any splitting due to ¹³C-¹⁵N coupling. This evidence thus indicates that rearrangement of phenylalanine to phenylglycine proceeds by an intermolecular pathway, unless transamination of phenylalanine and phenylglycine occurs so rapidly that the ¹⁵N label is exchanged completely before incorporation into the antibiotic takes place.

Although it is not possible to determine the extent of transamination, if any, in phenylglycine, the extent of transamination in phenylalanine can be determined by an analysis of the ¹⁵N content of the N-methylphenylalanine portion of virginiamycin S₁. A direct analysis by ¹³C nmr was not possible since two-bond ¹³C-¹⁵N coupling constants are quite small, but analysis by mass spectrometry gave the desired information. Acid hydrolysis of the antibiotic followed by derivatization of the resulting amino acids yielded a mixture of N-trifluoroacetylamino acid butyl esters. Analysis of this mixture by gc/ms gave the data shown in Table 1 for N-trifluoroacetyl-N-methylphenylalanine butyl ester; the data shown are for the base peak due to the ion [C₆H₅CH₂CHN(CH₃) COCF₃]⁺ and its isotopes, formed by loss of the carbobutoxy group. These data show that the ion in question (and hence the intact amino acid) consists of approximately 14% singly labeled species (either ¹³C or ¹⁵N) and 9% doubly labeled species, and thus, a substantial amount of ¹⁵N label is retained in the N-methylphenylalanine portion of virginiamycin S₁.² A comparable retention of label in phenylglycine would have yielded a readily detectable splitting of the ¹³C signal at 56.1 ppm in virginiamycin S₁.

 TABLE 1.
 Relative Abundance for the Ions

 [C₆H₅CH₂CHN(CH₃)COCF₃]⁺

 from Labeled and Unlabeled N-Methyl

 N-trifluoroacetylphenylalanine butyl ester^a

m/z	Unlabeled	Labeled	Corrected labeled ^b	%
230	100	100	100	77
231	13.0	31.2	18.2	14
232	1.2	13.6	11.2	9

^aNumbers given are an average of 6-8 runs.

 $^{\rm b}$ Corrected for the natural abundance contribution of $^{13}\text{C}.$

²Similar measurements on the corresponding ion from N-trifluoroacetylphenylglycine butyl ester confirmed that essentially all of the ¹⁵N label was lost in the formation of phenylglycine.

and thus, the observed absence of splitting confirms that the rearrangment of phenylalanine to phenylglycine occurs by an intermolecular pathway.

The rearrangement of phenylalanine to phenylglcyine in this stystem thus conforms to the type of pathway observed in the conversion of tyrosine to β -tyrosine (10), rather than the intramolecular pathway observed in the conversion of lysine to β -lysine (11).

EXPERIMENTAL

GENERAL EXPERIMENTAL PROCEDURES.—Nmr spectra were determined on an IBM WP-270 spectrometer. Gc/ms was carried out on a Finnigan-MAT 112 mass spectrometer coupled to a Varian 2100 gas chromatograph. Melting points were determined on a Kofler block and are uncorrected. Hplc was carried out on an apparatus consisting of a Waters M6000A pump, a Valco six-port injection valve, and a Waters 440 absorbance detector. Waters Nova-Pak Radial-Pak columns were used for analytical hplc, with acetonitrile-H₂O (40:60) containing 0.05% di-n-butylamine as solvent. Fermentation was carried out in a fermenter (New Brunswick Scientific).

 $[\beta$ -¹³C, ¹⁵N]- α -ACETAMIDOCINNAMIC ACID AZLACTONE.—We heated $[\alpha$ -¹³C]benzaldehyde (1.20 g, 11.2 mmol), $[1^5$ N]-N-acetylglycine (0.906 g, 768 mmol) (15), anhydrous NaOAc (0.470 g), and Ac₂O (1.9 g) under N₂ for 2 h. After cooling, the flask was stored at 4° overnight, and the contents were then treated with H₂O (2 ml). The solid product was broken up, filtered, and rinsed with two 1-ml portions of cold H₂O, yielding 1.062 g (73%) of crude product.

 $[\beta^{-13}C, {}^{15}N]$ - α -ACETAMIDOCINNAMIC ACID.—The crude azlactone (1.062 g) was heated under reflux for 6 h in Me₂CO (10 ml) and H₂O (4 ml). The Me₂CO was evaporated, 25 ml H₂O added, and the suspension boiled. The hot solution was filtered, the residue rinsed with a small amount of boiling H₂O, and the filtrate treated at 100° with 0.2 g Norit A for 5 min. The charcoal was filtered from the hot solution, and the filtrate was evaporated to 20 ml in vacuo and allowed to stand at 4° overnight. The white crystalline solid was filtered off and dried to give 0.977 g (84%) product, mp 193-194° [lit 193-194° (17)].

DL-[β -¹³C, ¹³N]PHENYLALANINE HYDROCHLORIDE.—The acetamidocinnamic acid, (0.878 g) was hydrogenated in glacial HOAc (10 ml) over 5% palladium on carbon (0.25 g) for 2.5 h. at 25°. The catalyst was removed by filtration, the filtrate evaporated to dryness, and the residue heated under reflux in 20 ml 1 N HCl for 11 h. The mixture was evaporated to dryness in vacuo, and the residue dried in vacuo over NaOH to give 0.645 g (75%) of labeled phenylalanine hydrochloride, identical on tlc and co-tlc with an authentic sample. ¹³C nmr (D₂O) δ 171.27 (s), 134.00 (d, J=43.4 Hz), 129.35 (d, J=3.1 Hz), 129.16 (d, J=3.7 Hz), 127.94 (s), 54.13 (dd, J_{CC}=32.9 Hz, J_{CN}=6.5 Hz), 35.50 (s).

CULTURE CONDITIONS.—The organism used in this work, *S. virginiae* strain 1830, was obtained from SmithKline Animal Health Products, West Chester, Pennsylvania. It was maintained on potato-glucose-agar slants of the following composition: filtrate from 200 g boiled potatoes, glucose 10 g, agar 20 g, H₂O to 1 liter. Newly inoculated slants were incubated at 28° for 7 days and stored at 4° until needed. A vegetative inoculum was prepared by transferring mycelium and spores from a slant to a 250 ml baffled Erlenmeyer flask containing 30 ml of vegetative medium STA-2 (corn steep liquor 36 g, peanut oil cake 8 g, glucose 50 g, CaCO₃ 5 g, MnSO₄ 0.01 g, H₂O to 1 liter). The vegetative inoculum was incubated at room temperature on a rotary shaker at 330 rpm for 72 h, and the contents were aseptically transferred to the fermenter vessel containing 1.5 liters of medium STA-14 (36 g corn steep liquor, 5 g yeast autolysate, 10 g peanut oil cake, 5 g CaCO₃, 10 g linseed oil, 5 g glucose, 25 g glycerol, H₂O to 1 liter). The broth was aerated at 1.25 liter/min and stirred at 450 rpm. Temperature was maintained at 21-22°. After 10 h, a solution of 0.29 g of DL-[β -1³C, 1⁵N]phenylalanine and 0.23 g L-threonine in 5 ml H₂O was introduced through a 0.45 μ filter. Fermentation was continued for a total of 48 h, with addition of sterile 1 N NaOH (5 ml) at 26 h and 36 h.

ISOLATION OF VIRGINIAMYCIN S₁.—The fermentation broth was filtered through Hyflo Super Cel and the filtrate extracted twice with one-third volume of hexane and then three times with a half volumes of EtOAc. The combined EtOAc extracts were dried (MgSO₄) and evaporated. The residue was dissolved in CHCl₃ (5 ml) and placed on a silica gel column, 25 mm×250 mm. Elution with CHCl₃-MeOH (99:1) and collection of 20 ml fractions yielded virginiamycin S₁ in fractions 14-16. The isolated material was shown to be >90% pure by analytical hplc and tlc (silica gel, CHCl₃-MeOH, (95:5); quantification by hplc gave a yield of 7.6 mg.

PREPARATION AND MASS SPECTROMETRIC ANALYSIS OF N-TRIFLUOROACETYLAMINO ACID BUTYL ESTERS.—Virginiamycin S₁ (30 mg) in 6 N HCl (2 ml) was heated at 104° for 24 h, and the mixture evaporated to dryness in vacuo. The residue was treated with 2 ml dry 3 N HCl in BuOH, heated at 110° for 3 h, and excess reagent removed in a stream of N_2 . Treatment with trifluoroacetic anhydride (1 ml) in CH_2Cl_2 (1 ml) at room temperature for 24 h, and removal of excess reagent with N_2 yielded crude mixed *N*-trifluoroacetylamino acid butyl esters. Similar sequences were carried out on labeled virginiamycin S_1 (2.5 mg), and, without the initial hydrolysis step, on *N*-methyl-L-phenylalanine and on L-phenylglycine.

The mixed N-trifluoroacetylamino acid butyl esters were separated by gc on a 6 ft×2 mm i.d. glass column with 10% SP-2100 on Supelcoport (80-100 mesh), with a temperature program from 75° to 250° at 10°/min, and a helium flow of 20 ml/min. The gc peaks due to the derivatives of N-methyl-L-phenylalanine and L-phenylglycine were analyzed by ms, and the isotopic composition of the major fragment ion in each spectrum was determined on an average of 6-8 spectra by the method of Biemann (18).

ACKNOWLEDGMENTS

We thank Dr. Richard Wang, SmithKline Animal Health Products, for a culture of *S. virginiae* strain 1830, and Southern of Rocky Mount for a gift of peanut oil cake. We are particularly grateful to Professor Robert White of the Biochemistry Department, Virginia Polytechnic Institute and State University, for assistance with the gc/ms analysis, and to SmithKline Animal Health Products for a grant-in-aid in support of this work.

LITERATURE CITED

- 1. J.W. LeFevre and D.G.I. Kingston, J. Org. Chem., 49, 2588 (1984).
- 2. C. Cocito, Microbiol. Rev., 43, 145 (1979).
- 3. P. Crooy and R. de Neys, J. Antibiot., 25, 371 (1972).
- 4. H. Vanderhaeghe and G. Parmentier, J. Am. Chem. Soc., 82, 4414 (1960).
- 5. J.P. Declerq, G. Germain, M. Van Meerssche, S.E. Hull, and M.J. Irwin, *Acta. Cryst. Sect. B*, **34**, 3644 (1978).
- 6. M.J.O. Anteunis, R.E.A. Callens, and D.K. Tavernier, Eur. J. Biochem., 58, 529 (1975).
- 7. Q.R. Bartz, J. Standiford, J.D. Mold, D.W. Johannessen, A. Ryder, A. Maretzki, and T.H. Haskell, Antibiotics Annual 1954/55, 777 (1955).
- 8. J.C. Sheehan, H.G. Zachan, and W.B. Lawsan, J. Am. Chem. Soc., 80, 3349 (1958).
- 9. D.J. Hook and L.C. Vining, Can. J. Biochem., 51, 1630 (1973).
- 10. R.J. Parry and Z. Kurylo-Borowska, J. Am. Chem. Soc., 102, 836 (1980).
- 11. T.R. Thiruvengadam, S.J. Gould, D.J. Aberhart, and H.J. Lin, J. Am. Chem. Soc., 105, 5740 (1983).
- 12. A.A. Molinero, "The Biosynthesis of Virginiamycin S₁," M.S. Thesis, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, 1982, p. 60.
- 13. A. Yoshitake, Y. Makari, K. Kawahara, and M. Endo, J. Labelled Comp., 9, 537 (1973).
- 14. R.M. Herbst and D. Shemin, Org. Synth. Coll., 2, 1 (1943).
- 15. H.B. Gillespie and H.R. Snyder, Org. Synth. Coll., 2, 489 (1943).
- 16. M. Calvin, "Isotopic Carbon," New York, John Wiley and Sons, 1960, p. 180.
- 17. R.C. Weast and M.J. Astle, eds., "CRC Handbook of Chemistry and Physics," CRC Press, Inc., Boca Raton, Florida, 1982, p. C-233.
- 18. K. Biemann, "Mass Spectrometry: Organic Chemical Applications," McGraw-Hill, New York, 1962, pp. 1-370.

Received 23 December 1985